|3Apr 29, 4:54 PM ET

Taiho Ventures LLC 3

3 · Werewolf Therapeutics, Inc. · Filed Apr 29, 2021

Insider Transaction Report

Form 3
Period: 2021-04-29
Holdings
  • Series A Preferred Stock

    Common Stock (1,318,311 underlying)
  • Series B Preferred Stock

    Common Stock (438,098 underlying)
Footnotes (2)
  • [F1]The Series A Preferred Stock is convertible into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
  • [F2]The Series B Preferred Stock is convertible into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

Documents

1 file
  • 3
    doc3.xmlPrimary

    FORM 3 SUBMISSION